Royalty Pharma (RPRX) EVP Hite sells 130,000 shares in 10b5-1 trades

Q: What insider transaction did RPRX executive Christopher Hite report?

Christopher Hite reported open-market sales totaling 130,000 Class A Ordinary Shares of Royalty Pharma plc. The transactions occurred on June 30, 2026 and were disclosed as routine insider activity in a Form 4 filing with detailed share counts and prices.

Q: At what prices were the RPRX shares sold in this Form 4?

The RPRX shares were sold at weighted average prices generally between about $56.07 and $57.22 per share . Footnotes explain that each reported price reflects multiple trades within those ranges and that full pricing breakdowns are available upon written request.

Q: Was the Christopher Hite RPRX stock sale made under a 10b5-1 plan?

Yes. All reported transactions were effected under a Rule 10b5-1 trading plan adopted on March 20, 2026. Such plans schedule trades in advance, indicating the timing of these sales was pre-arranged rather than based on day-to-day market decisions.

Q: How many Royalty Pharma (RPRX) shares were sold directly vs indirectly?

Of the 130,000 RPRX shares sold, a portion was sold from direct holdings and a portion from indirect holdings through SCH Investment Partners LLC. The filing itemizes each block of shares by ownership type and post-transaction share balances.

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Royalty Pharma plc executive Christopher Hite reported pre-planned open-market sales of 130,000 Class A Ordinary Shares on June 30, 2026 under a Rule 10b5-1 trading plan. The sales occurred at weighted average prices generally between about $56 and $57 per share.

After these transactions, Hite holds 40,000 Class A Ordinary Shares directly. Additional shares are held indirectly through SCH Investment Partners LLC, which reported post-transaction ownership of 461,953 Class A Ordinary Shares. Some of the sales in this filing were executed by that LLC rather than by Hite personally.

Insider Trade Summary 10b5-1

Net Seller: 130,000 shares ($7,345,471)

Net Sell 4 txns

Insider Hite Christopher

Role EVP & Chairman, Partnering

Sold 130,000 shs ($7.35M)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares	97,446	$56.5028	$5.51M
Sale	Class A Ordinary Shares	2,554	$57.1031	$146K
Sale	Class A Ordinary Shares	29,400	$56.4423	$1.66M
Sale	Class A Ordinary Shares	600	$57.09	$34K

Holdings After Transaction: Class A Ordinary Shares — 461,953 shares (Indirect, By SCH Investment Partners LLC); Class A Ordinary Shares — 40,600 shares (Direct, null)

Footnotes (1)

All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $57.05 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.06 to $57.22 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $56.95 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.03 to $57.11 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 130,000 shares First sale block: 600 shares at $57.0900 Second sale block: 29,400 shares at $56.4423 +5 more

8 metrics

Shares sold 130,000 shares Total Class A Ordinary Shares sold on June 30, 2026

First sale block 600 shares at $57.0900 Open-market sale of Class A Ordinary Shares

Second sale block 29,400 shares at $56.4423 Open-market sale of Class A Ordinary Shares

Third sale block 2,554 shares at $57.1031 Indirect sale by SCH Investment Partners LLC

Fourth sale block 97,446 shares at $56.5028 Indirect sale by SCH Investment Partners LLC

Direct holdings after 40,000 shares Class A Ordinary Shares held directly post-transaction

Indirect holdings after 461,953 shares Class A Ordinary Shares held via SCH Investment Partners LLC

Net buy/sell direction net-sell of 130,000 shares Form 4 transaction summary for June 30, 2026

Key Terms

Rule 10b5-1 plan, weighted average price, Class A Ordinary Shares, open-market sale, +1 more

5 terms

Rule 10b5-1 plan regulatory

"All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $57.05 per share."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Class A Ordinary Shares financial

"security_title: Class A Ordinary Shares"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect financial

"ownership_type: indirect, nature_of_ownership: By SCH Investment Partners LLC"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:09 PM Accepted by SEC EDGAR 07/02/2026 - 04:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hite Christopher

(Last)

(First)

(Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK

10022

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP & Chairman, Partnering

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Ordinary Shares	06/30/2026		S⁽¹⁾		97,446	D	$56.5028⁽²⁾	461,953	I	By SCH Investment Partners LLC
Class A Ordinary Shares	06/30/2026		S⁽¹⁾		2,554	D	$57.1031⁽³⁾	459,399	I	By SCH Investment Partners LLC
Class A Ordinary Shares	06/30/2026		S⁽¹⁾		29,400	D	$56.4423⁽⁴⁾	40,600	D
Class A Ordinary Shares	06/30/2026		S⁽¹⁾		600	D	$57.09⁽⁵⁾	40,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 20, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $57.05 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.06 to $57.22 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.07 to $56.95 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.03 to $57.11 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 866,410 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,238,789 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did RPRX executive Christopher Hite report?

Christopher Hite reported open-market sales totaling 130,000 Class A Ordinary Shares of Royalty Pharma plc. The transactions occurred on June 30, 2026 and were disclosed as routine insider activity in a Form 4 filing with detailed share counts and prices.

At what prices were the RPRX shares sold in this Form 4?

The RPRX shares were sold at weighted average prices generally between about $56.07 and $57.22 per share. Footnotes explain that each reported price reflects multiple trades within those ranges and that full pricing breakdowns are available upon written request.

Was the Christopher Hite RPRX stock sale made under a 10b5-1 plan?

Yes. All reported transactions were effected under a Rule 10b5-1 trading plan adopted on March 20, 2026. Such plans schedule trades in advance, indicating the timing of these sales was pre-arranged rather than based on day-to-day market decisions.

How many Royalty Pharma (RPRX) shares does Christopher Hite hold after the sale?

Following the reported sales, Christopher Hite directly owns 40,000 Class A Ordinary Shares. The filing also shows 461,953 shares held indirectly through SCH Investment Partners LLC, reflecting a substantial remaining ownership position associated with the reporting person.

What role does SCH Investment Partners LLC play in the RPRX Form 4 filing?

SCH Investment Partners LLC is identified as holding RPRX shares indirectly for the reporting person. The LLC executed part of the June 30, 2026 open-market sales and reported owning 461,953 Class A Ordinary Shares after the transactions were completed.

How many Royalty Pharma (RPRX) shares were sold directly vs indirectly?

Of the 130,000 RPRX shares sold, a portion was sold from direct holdings and a portion from indirect holdings through SCH Investment Partners LLC. The filing itemizes each block of shares by ownership type and post-transaction share balances.